On-Site Drug Testing: Benefits, Challenges, and Regulatory Compliance

On-site drug testing — the practice of collecting specimens at or near the workplace rather than at a dedicated collection site — appeals to employers for one simple reason: convenience. No driver being pulled off the road to travel to a clinic. No supervisor losing multiple employees to an off-site appointment. No coordination gaps between the workplace and an external facility. For many regulated employers, especially those operating vehicle fleets or managing geographically dispersed crews, on-site testing is a logical extension of occupational health services. But the operational appeal of on-site testing exists in tension with the technical constraints of federal regulation, and that tension is where many programs encounter unexpected compliance problems.

On-site testing is not a shortcut around DOT rules — it is an alternative delivery method that must satisfy the same regulatory frameworks as any other collection. Under 49 CFR Part 40, urine specimens must be collected using a Custody and Control Form, the chain of custody must remain unbroken, the specimen must be shipped to a SAMHSA-certified laboratory, and results must still be reviewed by a qualified Medical Review Officer before being reported to the employer. The regulatory infrastructure doesn't change; only the location of the initial collection does. This article walks through what on-site programs can accomplish, where the regulatory constraints bite hardest, and how to design an on-site operation that stays defensible in an audit.

What On-Site Testing Is — And What It Is Not

On-site drug testing typically refers to urine specimen collection conducted at or very near the employer's premises, often as part of a mobile drug testing unit or a dedicated collection room staffed by a trained collector. The specimen is collected under federal procedures, sealed into a chain-of-custody container, and then transported to a SAMHSA-certified laboratory — exactly as it would be from any other collection location. The difference is purely geographic: the employee does not have to leave the property, and the employer can observe the process and timing more directly.

On-site testing does not include rapid or instant screening results delivered on the spot. Any urine specimen collected under DOT rules must be analyzed at a certified laboratory, and no employer-operated on-site equipment can provide a legally defensible federal DOT result. Some employers use non-regulated screening tools for internal wellness programs or pre-employment pools as a filter before sending confirmed positives for official federal testing — a practice that is legal, but those screening results are not themselves DOT-compliant test results. The official result only exists after the certified lab processes the specimen and the MRO reviews it.

Operational Advantages of On-Site Testing

The appeal of on-site programs is real and measurable. First, turnaround time compresses. An employee selected for random testing can be notified and collected within an hour or two, rather than being dispatched to an off-site facility. For fleet operations and shift work, this dramatically reduces operational disruption and eliminates the scheduling friction that often causes delays in completing required selections.

Second, visibility and control improve. The employer directly oversees collection procedures, can observe the chain of custody as the specimen is sealed and labeled, and knows immediately when a collection is completed. There is no third-party facility to coordinate with, no communication gaps between the testing site and the employer's operations, and no questions about whether a specimen was actually collected or whether procedures were followed. For compliance-conscious employers, that transparency is worth significant operational overhead.

Third, for employers in remote areas or with geographically scattered employees, on-site collection using mobile units can be the only practical way to meet testing obligations without asking employees to travel many hours. Pipeline operations, oil and gas remote camps, and rural construction sites often lack nearby collection facilities, making on-site programs not just convenient but necessary.

Finally, on-site testing can reduce costs by consolidating multiple employees into a single collection event, rather than paying facility fees for separate off-site appointments. For large employers running high-volume programs, the economics of operating a dedicated collection room or contracting with a mobile testing provider can exceed the cost savings of off-site fees — but the math depends heavily on program size and frequency.

Regulatory Constraints That Don't Disappear

The crucial limitation is this: every constraint of 49 CFR Part 40 applies to on-site collection just as it applies to any other. The Custody and Control Form must be completed in full, with all required signatures and information. The specimen must be properly sealed, labeled with the donor's identity, and protected from tampering or contamination. The chain of custody documentation must account for every moment the specimen is in someone's possession. And the specimen must reach a SAMHSA-certified laboratory within the regulatory timeframe — typically 72 hours from collection, and longer if shipping is delayed.

• Collector qualification — any individual who collects for DOT purposes must be trained and, ideally, certified. On-site staff collecting specimens are not automatically qualified; they need formal instruction in DOT procedures, chain-of-custody rules, and proper form completion.
• Collection privacy and observation — DOT rules specify what observers are present and what they observe during collection. An employer cannot simply watch from across the room; the rules define direct-observation conditions under which testing can occur and the protocols that govern those conditions.
• Specimen shipping and handling — the sealed specimen in its chain-of-custody container must be shipped to the lab under conditions that protect the specimen and the documentation. Leaving a specimen at an on-site facility for days before shipment, or allowing it to sit in a warm vehicle, can compromise the chain of custody or raise questions about specimen integrity.
• Medical Review Officer review — even a specimen collected at the employer's own facility must be sent to a SAMHSA-certified laboratory and reviewed by an MRO outside the employer's organization. An employer cannot have an internal medical officer review its own specimens; the independence of the reviewing physician is a core safeguard.

Practical On-Site Program Design

Employers serious about on-site testing typically adopt one of two models. The first is an in-house collection room staffed by trained collectors. This requires investing in collector training, maintaining proper facilities (bathroom access, privacy, secure specimen storage, temperature-controlled space), and ensuring the staff is properly certified and kept current on regulatory changes. The second is a contract with a mobile drug testing provider — a company that brings trained collectors and equipment to the employer's site on a scheduled or on-call basis.

Either way, the employer must establish clear procedures for who is authorized to request a collection, how the selection is documented, how the employee is notified, and how the specimen is transferred from collection to shipment to the laboratory. These procedures need to be written, consistent, and auditable. When an examiner asks to see random selections, the on-site collection record must match the original selection record, and both must trace back to the pool and the selection method.

A critical detail that catches many employers off guard: on-site collection does not eliminate the need for a specimen custody chain. Even though the collection and the initial seal happen at the employer's facility, the sealed specimen must be handled as it would be anywhere else — signed over to whoever transports it, logged when it leaves the facility, and documented as received at the laboratory. If an employer's procedure is to 'keep the specimen in the office until Friday and then ship it to the lab,' that creates a chain-of-custody gap that an auditor will flag. The sealed specimen is still in somebody's possession; that possession must be documented.

Mobile Drug Testing Units

Many employers contract with third-party mobile testing providers to bring a collection unit to the workplace on a recurring schedule or as needed. The provider supplies trained collectors, handles the chain of custody, and ships the specimen to their affiliated SAMHSA-certified laboratory. The appeal is clear: the employer avoids hiring and training staff, and the provider assumes the regulatory burden. But the employer is still responsible for ensuring that every element of 49 CFR Part 40 is followed. That means the employer should ask the provider for documentation of collector certification, observe compliance with the Custody and Control Form procedures, and verify that the laboratories used are certified. A mobile unit doesn't excuse the employer from oversight; it just outsources some of the operational work to a specialist.

When On-Site Testing Runs into Trouble

Several common problems emerge in on-site programs, often because the regulatory requirements feel less formal when collection happens at the employer's own facility. A supervisor collects a specimen without proper training and without completing a full Custody and Control Form. A specimen sits in an unsecured desk drawer for a day before being shipped, creating a gap in the chain of custody. A positive result comes back, and the employer contacts the employee directly rather than routing through the Medical Review Officer, unintentionally contaminating the result. An employee refuses testing, and the employer tries to discipline the employee before documenting the refusal properly under Part 40. Any of these scenarios can undermine the legal defensibility of the result.

Another common problem arises from conflating on-site testing with on-site result reporting. An employer might arrange for a mobile unit to come and collect specimens, and then expect to receive preliminary results within hours so they can make immediate operational decisions — pull a driver off the road, exclude someone from a job. But preliminary screening results from an on-site collection are not defensible DOT results. The only result that has legal weight is the one certified by the SAMHSA lab and reviewed by the MRO, which typically takes several days. Acting on preliminary findings before the official result is confirmed exposes the employer to liability and can undermine the entire program's credibility.

On-Site Testing and the FMCSA Clearinghouse

For employers with FMCSA-regulated commercial drivers, on-site testing results must still be reported to the FMCSA Clearinghouse — the federal database through which employers query and report certain drug and alcohol violations. Whether the specimen was collected at a clinic across town or in the employer's own parking lot makes no difference to the Clearinghouse reporting obligation. If the program requires the employer to record a positive, a refusal, or an alcohol violation, that information must be submitted to the Clearinghouse within five business days of the MRO's report (or the supervisor's report of a refusal). Failures to report to the Clearinghouse are auditable findings and can result in fines, so the connection between the on-site collection and the federal database must be explicitly planned.

Building a Defensible On-Site Program

The decision to implement on-site testing should be guided by a clear understanding that 49 CFR Part 40 does not make exceptions for convenience. If your operation can benefit from on-site collection — faster turnaround, reduced employee disruption, better visibility into compliance — the operational case is strong. But the regulatory case is that on-site testing is merely the location where collection happens, not a shortcut around the procedures that make DOT results legally defensible.

A solid on-site program requires investment: trained collectors (whether in-house or contracted), secure collection facilities, documented procedures that map to federal requirements, regular audits of the collection process to catch compliance gaps before an examiner does, and a clear hand-off between the on-site collection team and the SAMHSA laboratory. Many employers find that partnering with a specialized compliance provider — either to staff on-site collection directly or to oversee an in-house operation — is the most efficient way to run the program correctly. When the regulatory burden and operational oversight are aligned, on-site testing delivers on its promise of faster, cleaner collections without compromising the defensibility of the results.